Skip to main content
Clinical Trials/KCT0001458
KCT0001458
Completed
未知

Clinical study for effects on menopasual symtom and blood vessel using combination of Kudzu and foxglove roots extract plus exercise

Ewha Womans University0 sites150 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Endocrine, nutritional and metabolic disease
Sponsor
Ewha Womans University
Enrollment
150
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) The particioants who give informed consent before the start
  • 2\) 45\~60 years old
  • 3\) Postmenopause (defined as at least 12 months amenorrhoea) or Perimenopause (defined as having no more than one menstrual period during the 3 months before recruitment and having follicle stimulating hormone\>40 IU/L) women
  • 4\) Women with moderate to severe menopausal symptoms (Kupperman index total score \= 20\)
  • 5\) Fasting LDL\-cholesterol level \= 130mg/dL
  • 6\) Women with low quality of the meal (recommended food score \= 36\)
  • 7\) Fasting blood glucose \= 100 mg/dl
  • 8\) glycated hemoglobin (HbA1c) \= 5\.7% and \= 6\.4%
  • 9\) BMI: \= 23kg/m2

Exclusion Criteria

  • 1\) Subjects who performed constant exercises at least 3 months prior to the first visit
  • 2\) Subjects who cannot participate in an exercise program
  • 3\) Subjects with surgical or chemotherapy induced menopause 4\) Subjects who have a history of breast cancer orabnormality depicted on a mammogram5\) Subjects who received hormone therapy within 6 months before the first visit
  • 6\) Subjects who take excessive amount of isoflavones (\=56 mg/day)
  • 7\) Subjects who consumed the functional food within 4 weeks prior to the first visit
  • 8\) Subjects who took medical supplies within 4 weeks prior to the first visit : Sleep iaid drug, antidepressant,selective estrogen receptor modulator, hypocholesterolemic drug, antihypertensive drugs, antidiabetes drugs, bisphosphonate, calcitonin
  • 9\) Subjects who have been vaginal bleeding without diagnosis
  • 10\) Subjects who have a history of endometrial hyperplasia, endometrial cancer, sex steroid dependant organ tumors
  • 11\) Subjects who have a history of severe migraine, thromboembolism, cerebrovascular disease, cardiovascular disease within 1 year prior to the first visit
  • 12\) Subjects with hepatic or renal dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level \> 2 times the upper limit of normal, Creatinine \> 2\.0 mg/dL)

Outcomes

Primary Outcomes

Not specified

Similar Trials